Reagents

Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S.

Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S.

Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S.

Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S.

Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann–La Roche and Chugai for the trea&tradeent of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in

A Proliferation-inducing Ligand (April)) also known as TNSF13A, Tall-2, and TRDL-1, is a member of the TNF ligand (TNFL) superfamily. April is most similar to B-cell activation factor (BAFF) with which it shares 30% sequence identity, compete for

A Proliferation-inducing Ligand (April)) also known as TNSF13A, Tall-2, and TRDL-1, is a member of the TNF ligand (TNFL) superfamily. April is most similar to B-cell activation factor (BAFF) with which it shares 30% sequence identity, compete for

A Proliferation-inducing Ligand (April)) also known as TNSF13A, Tall-2, and TRDL-1, is a member of the TNF ligand (TNFL) superfamily. April is most similar to B-cell activation factor (BAFF) with which it shares 30% sequence identity, compete for

Atrial natriuretic peptide (ANP), a stimulator of particulate guanylate cyclase, has been found to protect against reoxygenation-induced hypercontracture in isolated cardiomyocytes by increasing cyclic guanosine monophosphate synthesis ANP also

Small ubiquitin-related modifier (SUMO) proteins are conjugated to numerous intracellular targets and serve to modulate protein interaction, localization, activity, and stability. SUMO (also known as &#39Smt3&#39 and &#39sentrin&#39 in other

Beta-amyloid peptide (beta-APP) is a 40-residue peptide implicated in the pathogenesis of Alzheimer&rsquos disease (AD) and aged Down&#39s Syndrome, which is promoted by the acquisition of an additional copy of chromosome 21. The peptide is a

Beta-amyloid peptide (beta-APP) is a 40-residue peptide implicated in the pathogenesis of Alzheimer&rsquos disease (AD) and aged Down&#39s Syndrome, which is promoted by the acquisition of an additional copy of chromosome 21. The peptide is a